PLK1 and cancer: Cell cycle associated proteins are frequently aberrantly expressed in cancer [16] and can be targeted using small molecular inhibitory compounds such as novel inhibitors of the BUB1-Polo-like-kinase 1 interaction [21] and other cell cycle kinase inhibitors currently tested in preclinical studies [22].